Use of hormonal protection for chemotherapy-induced gonadotoxicity

S. Samuel Kim, Jung Ryeol Lee, Byung Chul Jee, Chang Suk Suh, Seok Hyun Kim, Alison Ting, Brian Petroff

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

It is still controversial that GnRH agonist (GnRHa) protects ovarian function from chemotherapy-induced gonadotoxicity. Indeed, the results of many studies related to this issue are neither consistent nor convincing because of the weak study design and the inadequate sample size. We identified 11 prospective controlled studies (8 nonrandomized and 3 randomized) for the systemic review and meta-analysis. The meta-analysis showed that GnRHa cotreatment during chemotherapy can protect ovarian function. However, it is worthy to note that the result of this meta-analysis is influenced by nonrandomized studies. The protective effect of GnRHa will remain elusive until the currently ongoing large, prospective, randomized studies are completed. In addition, tamoxifen, a selective estrogen receptor modulator, may have the protective effect against loss of follicles and ovarian function, which was caused by chemotherapy.

Original languageEnglish (US)
Pages (from-to)740-752
Number of pages13
JournalClinical Obstetrics and Gynecology
Volume53
Issue number4
DOIs
StatePublished - Dec 2010

Fingerprint

Gonadotropin-Releasing Hormone
Meta-Analysis
Drug Therapy
Prospective Studies
Selective Estrogen Receptor Modulators
Ovarian Follicle
Tamoxifen
Sample Size

Keywords

  • cancer
  • chemotherapy
  • fertility preservation
  • GnRH agonist
  • gonadotoxicity
  • tamoxifen

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Use of hormonal protection for chemotherapy-induced gonadotoxicity. / Kim, S. Samuel; Lee, Jung Ryeol; Jee, Byung Chul; Suh, Chang Suk; Kim, Seok Hyun; Ting, Alison; Petroff, Brian.

In: Clinical Obstetrics and Gynecology, Vol. 53, No. 4, 12.2010, p. 740-752.

Research output: Contribution to journalArticle

Kim, S. Samuel ; Lee, Jung Ryeol ; Jee, Byung Chul ; Suh, Chang Suk ; Kim, Seok Hyun ; Ting, Alison ; Petroff, Brian. / Use of hormonal protection for chemotherapy-induced gonadotoxicity. In: Clinical Obstetrics and Gynecology. 2010 ; Vol. 53, No. 4. pp. 740-752.
@article{2242caf3c61a400eb1a1bd2b60323ddf,
title = "Use of hormonal protection for chemotherapy-induced gonadotoxicity",
abstract = "It is still controversial that GnRH agonist (GnRHa) protects ovarian function from chemotherapy-induced gonadotoxicity. Indeed, the results of many studies related to this issue are neither consistent nor convincing because of the weak study design and the inadequate sample size. We identified 11 prospective controlled studies (8 nonrandomized and 3 randomized) for the systemic review and meta-analysis. The meta-analysis showed that GnRHa cotreatment during chemotherapy can protect ovarian function. However, it is worthy to note that the result of this meta-analysis is influenced by nonrandomized studies. The protective effect of GnRHa will remain elusive until the currently ongoing large, prospective, randomized studies are completed. In addition, tamoxifen, a selective estrogen receptor modulator, may have the protective effect against loss of follicles and ovarian function, which was caused by chemotherapy.",
keywords = "cancer, chemotherapy, fertility preservation, GnRH agonist, gonadotoxicity, tamoxifen",
author = "Kim, {S. Samuel} and Lee, {Jung Ryeol} and Jee, {Byung Chul} and Suh, {Chang Suk} and Kim, {Seok Hyun} and Alison Ting and Brian Petroff",
year = "2010",
month = "12",
doi = "10.1097/GRF.0b013e3181f96cb1",
language = "English (US)",
volume = "53",
pages = "740--752",
journal = "Clinical Obstetrics and Gynecology",
issn = "0009-9201",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Use of hormonal protection for chemotherapy-induced gonadotoxicity

AU - Kim, S. Samuel

AU - Lee, Jung Ryeol

AU - Jee, Byung Chul

AU - Suh, Chang Suk

AU - Kim, Seok Hyun

AU - Ting, Alison

AU - Petroff, Brian

PY - 2010/12

Y1 - 2010/12

N2 - It is still controversial that GnRH agonist (GnRHa) protects ovarian function from chemotherapy-induced gonadotoxicity. Indeed, the results of many studies related to this issue are neither consistent nor convincing because of the weak study design and the inadequate sample size. We identified 11 prospective controlled studies (8 nonrandomized and 3 randomized) for the systemic review and meta-analysis. The meta-analysis showed that GnRHa cotreatment during chemotherapy can protect ovarian function. However, it is worthy to note that the result of this meta-analysis is influenced by nonrandomized studies. The protective effect of GnRHa will remain elusive until the currently ongoing large, prospective, randomized studies are completed. In addition, tamoxifen, a selective estrogen receptor modulator, may have the protective effect against loss of follicles and ovarian function, which was caused by chemotherapy.

AB - It is still controversial that GnRH agonist (GnRHa) protects ovarian function from chemotherapy-induced gonadotoxicity. Indeed, the results of many studies related to this issue are neither consistent nor convincing because of the weak study design and the inadequate sample size. We identified 11 prospective controlled studies (8 nonrandomized and 3 randomized) for the systemic review and meta-analysis. The meta-analysis showed that GnRHa cotreatment during chemotherapy can protect ovarian function. However, it is worthy to note that the result of this meta-analysis is influenced by nonrandomized studies. The protective effect of GnRHa will remain elusive until the currently ongoing large, prospective, randomized studies are completed. In addition, tamoxifen, a selective estrogen receptor modulator, may have the protective effect against loss of follicles and ovarian function, which was caused by chemotherapy.

KW - cancer

KW - chemotherapy

KW - fertility preservation

KW - GnRH agonist

KW - gonadotoxicity

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=78349280779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349280779&partnerID=8YFLogxK

U2 - 10.1097/GRF.0b013e3181f96cb1

DO - 10.1097/GRF.0b013e3181f96cb1

M3 - Article

C2 - 21048441

AN - SCOPUS:78349280779

VL - 53

SP - 740

EP - 752

JO - Clinical Obstetrics and Gynecology

JF - Clinical Obstetrics and Gynecology

SN - 0009-9201

IS - 4

ER -